Unintended Cardiovascular Effects of Mood, Sleep and Pain Medications

Kevin B. Sneed, PharmD, CRPh

Objectives
• Review basic pharmacological principles as it pertains to medicinal chemicals used for common patient care
• Discuss some of the psychiatric-related medication classes that can lead to cardiac adverse effects
• Discuss environmental factors that may complicate or exacerbate cardiac complications associated with

Pharmacology 101
• Some things do not change; a leading pharmacology textbook in 1941 began: “The subject of pharmacology is a broad one and embraces the knowledge of the source, physical and chemical properties, compounding, physiological actions, absorption, fate, and excretion, and therapeutic uses of drugs.” – Alfred Goodman Gilman
MJ Case Study: First Visit

- 53 yr old male presents: office visit for a DMT2. It was scheduled by pt’s spouse because pts father died at age 60 yrs due to an acute MI.
  - his father had not sought out the care of a physician except for acute care issues.
- The patient has not seen a doctor in 5 yrs, his last visit was for a sinus infection. At that visit he was told his blood pressure was elevated, the pt was unsure of that BP level and was given a card to check his BP outside the office and also given a lab slip –neither completed. He also reports some feelings of sadness at times, and does not sleep well.

MJ Visit One

- ROS: neg - CP, SOB, ankle swelling,
- ROS: + fatigue, trouble sleeping at times
- Social Hx: 10-15 cigs/day; 8-10 alcohol drinks/wk
- PE: Vitals: BP 148/86, P 82/min, R 18, afeb
- Weight : 238 lbs, Ht: 69 in. BMI: 34.6
- Waist Circumference: 41 in
- HEENT: neg; Neck: nl, no carotid bruits
- Lungs: clear Heart: NSR no murmur
- Abdomen: central obesity otherwise NL
- Ankles: no edema, good pulses

MJ Follow up visit #2

- 10 days later, labs completed
- BP: 146/84, Pulse: 84, Wt:239 lbs, Ht: 69 in
- CMP
  - Glucose: 124 –
  - Creatinine: 1.04 – nl ref (0.70-1.10)
  - Electrolytes normal
  - LFTs: ALT - 60 AST – 40
- CBC: completely normal
MJ Follow up visit #2

- Lipid panel –
  - Triglycerides: 190
  - Total cholesterol: 190
  - HDL: 38
  - Calculate the LDL?
    - LDL = TC – HDL - TG/5 Friedwald Formula
    - LDL = 190 - 38 - 190/5 (38)
    - LDL = 190 – 76 = 114
  - LDL: 114

Define “Adverse Drug Reaction”

- “...a response to a drug that is noxious and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for modification of physiological function.”

Medication Drug Disasters (Reference)

<table>
<thead>
<tr>
<th>Antidepressant</th>
<th>Location</th>
<th>Date</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenelzine</td>
<td>US</td>
<td>1960s</td>
<td>Treatment of depression, 31 deaths</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>United Kingdom</td>
<td>1960s</td>
<td>Myeloma and other neoplasms</td>
</tr>
<tr>
<td>Sulfadiazine</td>
<td>US</td>
<td>1960s</td>
<td>Neurological effects</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>United Kingdom</td>
<td>1960s</td>
<td>Myeloma and other neoplasms</td>
</tr>
<tr>
<td>Phenelzine</td>
<td>US</td>
<td>1960s</td>
<td>Treatment of depression, 31 deaths</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>United Kingdom</td>
<td>1960s</td>
<td>Myeloma and other neoplasms</td>
</tr>
<tr>
<td>Sulfadiazine</td>
<td>US</td>
<td>1960s</td>
<td>Neurological effects</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>United Kingdom</td>
<td>1960s</td>
<td>Myeloma and other neoplasms</td>
</tr>
<tr>
<td>Sulfadiazine</td>
<td>US</td>
<td>1960s</td>
<td>Neurological effects</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>United Kingdom</td>
<td>1960s</td>
<td>Myeloma and other neoplasms</td>
</tr>
<tr>
<td>Sulfadiazine</td>
<td>US</td>
<td>1960s</td>
<td>Neurological effects</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>United Kingdom</td>
<td>1960s</td>
<td>Myeloma and other neoplasms</td>
</tr>
<tr>
<td>Sulfadiazine</td>
<td>US</td>
<td>1960s</td>
<td>Neurological effects</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>United Kingdom</td>
<td>1960s</td>
<td>Myeloma and other neoplasms</td>
</tr>
<tr>
<td>Sulfadiazine</td>
<td>US</td>
<td>1960s</td>
<td>Neurological effects</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>United Kingdom</td>
<td>1960s</td>
<td>Myeloma and other neoplasms</td>
</tr>
<tr>
<td>Sulfadiazine</td>
<td>US</td>
<td>1960s</td>
<td>Neurological effects</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>United Kingdom</td>
<td>1960s</td>
<td>Myeloma and other neoplasms</td>
</tr>
<tr>
<td>Sulfadiazine</td>
<td>US</td>
<td>1960s</td>
<td>Neurological effects</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>United Kingdom</td>
<td>1960s</td>
<td>Myeloma and other neoplasms</td>
</tr>
<tr>
<td>Sulfadiazine</td>
<td>US</td>
<td>1960s</td>
<td>Neurological effects</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>United Kingdom</td>
<td>1960s</td>
<td>Myeloma and other neoplasms</td>
</tr>
<tr>
<td>Sulfadiazine</td>
<td>US</td>
<td>1960s</td>
<td>Neurological effects</td>
</tr>
</tbody>
</table>
Cardiotoxic drugs – A focus on Chemotherapeutic Agents

- Chemotherapeutic agents have the most concern of resulting in cardiotoxicity for patients
  - Physiologic challenges include
  - LV dysfunction (symptomatic and asymptomatic)
- Structural changes include valvular heart disease, conduction disturbances, or pericardial disease.

Problem Statement
- Unintended Cardiovascular Effects of Mood, Sleep and Pain Medications occur with patients
- WHAT are the most prevalent?
- ARE there co-morbidities associated with the use of these medications?
- WHAT does the future hold?

What Cardiac Effects concern us with psychiatric-related meds?

- HTN
- Metabolic Effects
- Serotonin-like effects
- Orthostatic Hypotension
- QT prolongation; arrhythmias
- SUDDEN DEATH
QT PROLONGATION – The one that REALLY concerns us!

QT PROLONGATION

• Can result from therapeutic use, combination or overdose
• Patients with QT prolongation are at increased risk of arrhythmias, particularly Torsades de Pointes, which in turn can devolve into life-threatening VF or asystole.
• Determining at what point the QT interval is long, and therefore a danger is controversial and poorly understood.

QT PROLONGATION – The one that REALLY concerns us!

QT PROLONGATION

• Likely the result of potassium-channel blockade
• Bradycardia
• Decrease potassium or magnesium

Classic example – Drug-induced Arrhythmia

Terfenadine and Quinidine
K+ channel blockade potency
Classic example – Metabolism Matters as potential causes of Arrhythmias

### Inhibitors of P450 Enzymes

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>CYP 1A2</th>
<th>CYP 2C9</th>
<th>CYP 2C19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluvoxamine</td>
<td>Fluconazole</td>
<td>Fluoxetine</td>
<td>Ketocanazole</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>Diltiazem</td>
<td>Omeprazole</td>
<td>Tinidazole</td>
</tr>
<tr>
<td>CYP 2D6</td>
<td>CYP 2E1</td>
<td>CYP 3A4</td>
<td></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>Diclofenac</td>
<td>Erythromycin</td>
<td>Grapefruit Juice</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>Propafenone</td>
<td>Droxanolide</td>
<td>Ketocanazole</td>
</tr>
<tr>
<td>Quinidine</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cardiotoxic drugs – A focus on QT interval disruption

- The most common drugs that prolong QRS and QT intervals and cause conduction block are
  - Tricyclic antidepressants
  - Antipsychotics (Typical vs. Atypical)
  - Antihistamines
  - Anticonvulsants
  - Dextropropoxyphene
  - Antimalarial drugs (chloroquine, quinine)
  - Calcium channel blockers
  - Beta blockers (propranolol, sotalol)
  - Digoxin
  - Antiarrhythmic drugs

Cardiotoxic drugs – A focus on QT interval disruption

- The most common drugs that prolong QRS and QT intervals and cause conduction block are
  - Tricyclic antidepressants
  - Antipsychotics (Typical vs. Atypical)
  - Antihistamines
  - Anticonvulsants
  - Dextropropoxyphene
  - Antimalarial drugs (chloroquine, quinine)
  - Calcium channel blockers
  - Beta blockers (propranolol, sotalol)
  - Digoxin
  - Antiarrhythmic drugs
Potential for TCA Cardiotoxicity

- QRS > 100 milliseconds or more in a limb lead
- Ventricular arrhythmia
  - Sensitivity 0.79 (95% CI 0.58-0.91)
  - Specificity 0.46 (95% CI 0.35-0.59)
- Seizures
  - Sensitivity 0.69 (95% CI 0.57-0.78)
  - Specificity 0.69 (95% CI 0.58-0.78)

TCA Cardiovascular toxicity

- Tachycardia:
  - Good indicator of TCA ingestion
  - Caused by cholinergic blockade
  - Catecholamine
  - Anxiety
- Hypotension
  - Vasodilation, hypovolaemia, alpha receptor blockade
  - Serious myocardial depression (normally wide QRS)
- Bradycardia:
  - generally associated major conduction block
  - severe toxicity

SSRIs, SNRI – Gain More with (LESS)

- SSRIs- have replaced TCAs for depressive symptoms and treatment
- More favorable side effect profile, in particular with cardiotoxic effect (less anticholinergic effect)
- As with many medications, sensitivity and/or specificity may decrease with increasing dosages of SSRIs
Cardiotoxic effects from Medications

- Long cardiac toxicity can manifest as ventricular dysfunction and clinical heart failure.

Antidepressant medication take Center of QT controversy

- FDA issues warning that citalopram "can cause abnormal changes to the electrical activity of the heart."
- Believed to be dose related (now restricted to 40mg/day upper limit dosing)
- "Patients at particular risk for developing prolongation of the QT interval include those with underlying heart conditions and those who are predisposed to low levels of potassium and magnesium in the blood,"

FDA MedWatch release, Aug 2011

What about Pain Medications and Toxicity?

![Morphine](image)
Pain Medication – Opioid Cardiovascular Toxicity

- Propoxyphene – most notorious recent cause of opioid cardiovascular toxicity
- Results in wide-complex dysrhythmias and negative contractility
  - Primarily through SODIUM channel antagonism (IA antiarrhythmics)
- Withdrawn from the market in 2010-11
- Concerns of fatality in overdose and adverse cardiac effects, including prolongation of the QT interval
- Based upon case reports, summary vital statistics, and surrogate endpoint studies

Pain Medication – Focus on Propoxyphene Cardiovascular Toxicity

- Withdrawn from the market in 2010-11
- Concerns of fatality in overdose and adverse cardiac effects, including prolongation of the QT interval
- Based upon case reports, summary vital statistics, and surrogate endpoint studies


Pain Medication – Focus on Propoxyphene Cardiovascular Toxicity

- Authors used a Tennessee Medicaid database (1992-2007).
  - Retrospective cohort study that compared risk of sudden cardiac, medication toxicity, and total out-of-hospital death
  - Compared propoxyphene users, comparable nonusers of any prescribed opioid analgesic, and users of hydrocodone.

### Pain Medication – Focus on Propoxyphene

**Cardiovascular Toxicity**

- **RESULTS**
  - No increased risk for *sudden cardiac death*
    - versus nonusers: hazard ratio [HR] = 1.00 [0.81-1.23];
    - versus current hydrocodone users: HR = 0.91 [0.68-1.21])
  - Increased risk for *medication toxicity deaths*
    - versus nonusers: HR = 1.85 [1.07-3.19], p = 0.027;
    - versus current hydrocodone users: HR = 2.10 [0.87-5.10], p = 0.100)
- **CONCLUSIONS:** Supported the concern that *propoxyphene* has greater toxicity in overdose.

---

### Pain Medication – Opioid

**Cardiovascular Toxicity**

- Other opioids at therapeutic concentrations, such as methadone, may interfere with normal cardiac repolarization and result in QT prolongation
- Separate from propoxyphene, which likely and specifically disrupts Na+ channel function

---

**So What does the Future Hold?**
Toxicogenomics and Nanotoxicology

- Constitute the toxicologic responses to rapid advances in genetics and material sciences.
- Toxicogenomics combines toxicology with genomics dealing with how genes and proteins respond to toxic substances.
  - Goal is to better decipher the molecular events underlying toxicologic mechanisms.
  - develop predictors of toxicity through the establishment of better molecular biomarkers,
  - understand genetic susceptibilities that pertain to toxic substances such as unanticipated idiosyncratic drug reactions.

Toxicogenomics and Nanotoxicology

- Nanotoxicology refers to the toxicology of engineered tiny particles.
  - Typical barriers at portals of entry may not prevent absorption or may themselves be adversely affected by the nanoparticles.
  - Target sites are the central nervous system or bone marrow.

Cardiotoxicity…What about Cardioprotection?

- RAAS – still a gold-standard with regards to cardioprotection
- Novel Biomarkers – microRNA biomarkers for early assessment of myocardial injury
- Herbal/ CAM methods for cardioprotection- can nutrition deliver?
Currently Prescribed Medications create harm...Why???

What We
Do Know
What We
Don’t Know

CLINICIANS DON’T KNOW
WHAT WE DON’T KNOW
CVD Patient

Results of Tests for a Trend in the Association between Myopathy and Each SNP Measured in the Genomewide Association Study

A New Way to Provide Medications to Patients...Pharmacogenomics!?

- Currently, medications are prescribed through “Trial and Error” methods
- Pharmacogenomics may provide the opportunity to individualize prospective medicine in order to
  - Maximize efficacy
  - Minimize adverse effects
  - Achieve therapeutic outcomes
### Medications- Variable Effects on Patients

<table>
<thead>
<tr>
<th>CONDITION</th>
<th>DRUG CLASS</th>
<th>RESPONSE RATE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASTHMA</td>
<td>BETA AGONIST</td>
<td>40% - 75%</td>
</tr>
<tr>
<td>HYPERTENSION</td>
<td>VARIOUS</td>
<td>30%</td>
</tr>
<tr>
<td>DEPRESSION</td>
<td>SSRI, Tricyclics</td>
<td>20% - 40%</td>
</tr>
<tr>
<td>DIABETES</td>
<td>Sulfonylureas, others</td>
<td>30% - 50%</td>
</tr>
<tr>
<td>CANCER</td>
<td>VARIOUS</td>
<td>Upto 70%</td>
</tr>
</tbody>
</table>

* = POOR RESPONSE RATE

### MJ Follow up visits #4 – 8

- Patient complains of “skipping heart beat at times”
  - “I don’t eat that much.”
  - Increased fatigue: TSH/CBC levels nl
  - What other disorder could be causing fatigue for this pt?
- **blood pressure became hypertensive**
  - an ACEI was started 2 yrs ago

### MJ Follow up visit #22
5 years from initial diagnosis

- Labs:
  - glucose: 280
  - HgbA1C: 9.0%
  - creatinine: 1.55
  - urine for microalbumin/creatinine: 69
  - TC: 216
  - HDL: 33
  - TG: 240
  - LDL: 135